MarketsandMarkets. Publisher Sample

Transcription

1 MarketsandMarkets Publisher Sample Phone: (US) or or (Int'l) Hours: Monday - Thursday: 5:30am - 6:30pm EST Fridays: 5:30am - 5:30pm EST customerservice@marketresearch.com MarketResearch.com

2 HUMAN MICROBIOME MARKET DISEASE (DIABETES, OBESITY, AUTOIMMUNE, CANCER, DIARRHEA, MENTAL DISORDER), APPLICATION (THERAPEUTIC, DIAGNOSTIC), PRODUCT (PROBIOTIC, PREBIOTIC, FOOD, MEDICAL FOOD, SUPPLEMENT, DEVICE, DRUG) GLOBAL FORECAST TO 2023 It s all about markets MARKETSANDMARKETS sales@marketsandmarkets.com

3 MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world. MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. MarketsandMarkets covers fourteen industry verticals, including aerospace and defence, advanced materials, automotives and transportation, banking and financial services, biotechnology, chemicals, consumer goods, energy and power, food and beverages, industrial automation, medical devices, pharmaceuticals, semiconductor and electronics, and telecommunications and IT. Copyright 2014 MarketsandMarkets All Rights Reserved. This document contains highly confidential information and is the sole property of MarketsandMarkets. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of MarketsandMarkets. 2

4 1 INTRODUCTION 1.1 OBJECTIVES OF THE STUDY To define, describe, and forecast the human microbiome market on the basis of applications, diseases, products, and geographies To provide detailed information regarding major factors influencing the growth of the market (drivers, restraints, opportunities, industry specific challenges, and burning issues) To strategically analyze the micromarkets1 with respect to individual growth trends, future prospects, and contributions to the overall market To analyze the opportunities in the market for stakeholders and details of the competitive landscape for the market leaders To forecast the revenue of the market segments with respect to four main geographies, namely, North America, Europe, Asia-Pacific, and Rest of the World (RoW) To strategically profile the key players and comprehensively analyze their market shares and core competencies2 To track and analyze competitive developments such as joint ventures, mergers and acquisitions, new product launches, and partnerships and collaborations in the human microbiome market 1. Microma rke t s are defined as the further segme n t s and subsegm e n t s of the human microbi o me market included in the report. 2. Core compet e n cie s of the compa nie s are captured in terms of their key develop me n t s, SWOT analysis, and key st rate gi e s adopted by them to sustain their position in the market. 1.2 MARKETS COVERED This research report categorizes the human microbiome market into the following segments: Human Microbiome Market, by Application Therapeutics Diagnostics Human Microbiome Market, by Disease Obesity Diabetes Autoimmune Disorders Cancer Acute Diarrhea Mental Disorder Others *Notes: Others include cardiovascular, other immune disorders (irritable bowel syndrome), metabolic syndrome (elevated blood lipids, high BP, and liver diseases), other mental disorders (bipolar disorders, schizophrenia, and drug metabolism), and atopic dermatitis 3

5 Human Microbiome Market, by Product Probiotics Prebiotics Foods Medical Foods Other Supplements Devices Drugs Human Microbiome Market, by Geography North America Europe Asia-Pacific Rest of the World (RoW) 4

6 2 RESEARCH METHODOLOGY 2.1 MARKET SIZE ESTIMATION FIGURE 1 BOTTOM-UP APPROACH Bottom-up Approach (Segmental Analysis) Global Human Microbiome Market Global Market Value Total Market Size ($Million) = Total Therapy Market for Each Disease (A) * Percentage of Population with Side-effects(B) Target Population = Percentage of Population with Side-effects (B) Percentage of Population with Side-effects (B) = X%*A Primary: Demand & Supply Side Experts Secondary: Annual Reports, Presentations, Press Releases, Journals, Paid Databases, and MarketsandMarkets Repository Total Therapy Market for Each Disease (A) Prevalence Rate for Each Disease, Globally Primary: Demand and Supply Side Experts Secondary: Annual Reports, Presentations, Press Releases, Journals, Paid Databases, and MarketsandMarkets Repository FIGURE 2 TOP-DOWN APPROACH Top-Down Approach (Segmental Analysis) Global Human Microbiome Market Total Global Human Microbiome Market ($Million) The Global Market Size is Validated through Primaries (Demand and Supply Side Experts) Percent Split for the Market Segments (Application and Product) of the Human Microbiome Market Secondary: Annual Reports, Presentations, Press Release, Journals, Paid Databases, and MarketsandMarkets Repository Primary: Demand &and Supply Side Experts Geographical Split Primary: Demand and Supply Side Experts Secondary: Company Websites, Press Releases, and News Articles Regional Market for Each Segment Secondary: Annual Reports, Presentations, Press Release, Journals, Paid Databases, and MarketsandMarkets Repository Primary: Demand and Supply Side Experts The bottom-up procedure was employed to arrive at the overall market size of the human microbiome market from the total therapy market and percentage of the population suffering with side-effects. 5

7 Calculations based on the total therapy market and the percentage of population suffering with side - effects led to the overall market size. This overall market size was used in the top-down procedure to estimate the sizes of the individual markets (mentioned in the market segmentation of products, applications, and geography) through percentage splits from secondary and primary research. For the calculation of each type of specific market segment, the most appropriate immediate parent market size was used for implementing the top-down procedure. The bottom-up procedure was also implemented for the data extracted from secondary research to validate the market segment revenues obtained. Market shares were then estimated for each company to verify the revenue shares used earlier in the bottom-up procedure. With the data triangulation procedure and validation of data through primaries, the exact values of the overall parent market size and each individual market size were determined and confirmed in this study. The data triangulation procedure implemented for this study is explained in the next section. 2.2 MARKET SHARE ESTIMATION KEY DATA FROM PRIMAR Y SOURCES PARAMETER DATA 1 Geographical Split Overall forecast of market and sub-segments in 2019 CAGR of each region in the forecast period ( ) Global human microbiome market, by geography North America, Europe, Asia-Pacific, and RoW 2 Global Market Size Forecast of the global market size for 2019 CAGR for the forecast period ( ) Global human microbiome market Human microbiome market by subsegments Human microbiome market, by disease 3 Market Split Application Disease Product Geography Global human microbiome market, by application Global human microbiome market, by disease Global human microbiome market, by product Global human microbiome market, by geography 6

8 KEY INDUSTRY INSIGHTS Probiotics will be the major market accounting for almost to of the total human microbiome product market. Prebiotics will be the fastestgrowing product segment and is estimated to grow at a CAGR of to. President and CEO, Leading Diagnostic Company The average growth for the human microbiome market will be between to. CEO, Gut-microbiome Research, Leading Provider of Molecular Diagnostic Products Most of the current microbiomebased products in the market are probiotics and supplements. Over the coming years, prebiotics, devices, and medical food products are expected to grow at a higher rate as compared to the probiotics product. Head Operations, Leading Manufacturer of Food and Beverage Products Currently, the market for obesity, autoimmune, and diabetes is significantly smaller as compared to the acute diarrhea market. However, it is expected to grow at a higher rate within the forecast period due to the growing incidence and prevalence of lifestyle and chronic diseases. Research Director, Leading Professional Pharmaceutical Company Emerging markets such as India and China unfold new avenues for the growth of the human microbiome market due to the growing prevalence of lifestyle and chronic diseases. General Manager & Senior Director of Business Development, Leading Healthcare Company 7

9 CAGR % ( ) Human Microbiome Market Global Forecast to EXECUTIVE SUMMARY FIGURE 3 HUMAN MICROBIOME MARKET, BY PRODUCT, 2019 Best markets to invest in next five years Best markets to invest in next five years Prebiotics Probiotics Medical Food Drugs Foods Other Supplements Market Size ($Million) Source: World Health Organization, World Cancer Research Fund International, United Nations Children's Fund International Agency for Research on Cancer, World Gastroenterology Organisation, International Diabetes Federation Food and Drug Administration, National Cancer Institute, Centers for Disease Control and Prevention, Journals, Company Annual Reports, Company Press Releases, Investor Presentations and MarketsandMarkets Analysis In this report, the human microbiome market is broadly segmented into obesity, diabetes, autoimmune disorders, cancer, acute diarrhea, mental disorders, and others such as cardiovascular diseases, other immune disorders (irritable bowel syndrome), metabolic syndrome (elevated blood lipids, high BP, and liver diseases), other mental disorders (bipolar disorders, schizophrenia, and drug metabolism), and atopic dermatitis. Acute diarrhea may account for the largest market size of the human microbiome market at an estimated $ million in 2019, growing at the highest CAGR of from 2019 to Factors such as rising prevalence of diabetes and obesity diseases, technological advancements, and new product launches stimulate the growth of the market. The obesity market is expected to account for the second largest share of of the global human microbiome market in The first obesity microbiome product is expected to hit the market in This will mainly be attributed to the growing awareness among patients regarding the use of microbiomebased prebiotics and probiotics products. The market is expected to experience a tremendous pull in growth post the regulatory approval of microbiome-based products for various diseases. 8

10 4 PREMIUM INSIGHTS 4.1 HUMAN MICROBIOME MARKET SNAPSHOT FIGURE 4 PREBIOTICS TO CAPTURE THE LION S SHARE GLOBALLY Probiotic North America Foods Europe Prebiotic Asia-Pacific Medical Food Rest of the World Drugs Market Share of Top 5 Human Microbiome Products Market Share of Region Source: World Gastroenterology Organisation, International Diabetes Federation, Food and Drug Administration, National Cancer Institute, Centers for Disease Control and Prevention, Company Annual Reports, Company Press Releases, Investor Presentations, MarketsandMarkets Analysis 9

11 5 MARKET OVERVIEW 5.1 INTRODUCTION HUMAN MICROBIOME MARKET, BY DISEASE Based on the type of disease, the human microbiome market comprises obesity, diabetes, autoimmune disorder, cancer, acute diarrhea, mental disorder, and others. FIGURE 5 HUMAN MICROBIOME MARKET SEGMENTATION: BY DISEASE HUMAN MICROBIOME MARKET, BY DISEASE Diabetes Obesity Autoimmune Disorder Cancer Acute Diarrhea Mental Disorder Others Source: Annual Reports, SEC Filings, Press Releases, Investor presentations, Expert Interviews, and MarketsandMarkets Analysis Note: cardiovascular diseases, other immune disorders (irritable bowel syndrome), metabolic syndrome (elevated blood lipids, high BP, liver diseases), other mental disorders (bipolar disorders, schizophrenia, drug metabolism), and atopic dermatitis 10

12 HUMAN MICROBIOME MAR KET, BY PRODUCT On the basis of products, the market is further segmented into probiotics, prebiotics, foods, medical food, other supplements, devices, and drugs,. FIGURE 6 HUMAN MICROBIOME MARKET SEGMENTATION: BY PRODUCT Probiotics Prebiotics Foods Medical Food Other Supplements Devices Drugs Source: Annual Reports, SEC Filings, Press Releases, Investor presentations, Expert Interviews, and MarketsandMarkets Analysis 5.2 MARKET DYNAMICS BURNING ISSUES A b u n d a n t o p p o r t u n i t i e s i n t h e m i c r o b i o m e f i e l d a n d t r e m e n d o u s r e s e a r c h i n v e s t m e n t s m a y b o o s t t h e m a r k e t FIGURE 7 FUNDS PROVIDED FOR MICROBIOME RESEARCH BY VARIOUS MEDICAL RESEARCH AGENCIES NIH MetaHIT (EU) Canadian Microbiome Initiative Other Members of IHMC (Australia, Japan, and Others) Private Venture Capitalists Private Foundations Source: National Institutes of Health, MarketsandMarkets Analysis 11

13 V a r i o u s m i c r o b i o m e t h e r a p e u t i c p r o d u c t s i n v a r i o u s s t a g e s o f d e v e l o p m e n t Getting microbiome-inspired therapies to the market presents a number of challenges; however, there are live Bio-Therapeutic Products (LPBs) and recombinant LBPs in various stages of development. Company LBP Agent Indications Development Stage Actogenix (Belgium) Engineered Lactococc us lactis expressing trefoil factor Oral mucositis Phase 1 Enterologic s (U.S.) E. coli M17 Pouchitis Preclinic al Osel (U.S.) Lactobacillus crispatus Clostridium butyric um Engineered Lactobacillus jensenii expressing a modified form of cyanovirin N Urinary tract infections, bacterial vaginosis CDI, antibioticassociated diarrheahiv prevention Phase 2 Phase 2 Preclinic al Oxthera Stockholm, Sweden (Sweden) Oxalobactor formig enes Hyperoxaluria Preclinic al Vedanta Bioscien ces (U.S.) Consortium of Clostridium strains IBD Preclinic al Viropharm a (U.S.) Nontoxig enic Clostridium difficile CDI Phase 1 Vithera Pharmaceuticals Cambridg e, MA, U.S. Engineered Lactococc us lactis expressing elafin IBD Preclinic al Source: Secondary Literature, Expert Interviews, and MarketsandMarkets Analysis At present, there are various institutions receiving funding for microbiome research. Among these, Washington University is one of the leading institutions receiving microbiome funding. 12

14 6 HUMAN MICROBIOME MARKET, BY DISEASE 6.1 INTRODUCTION FIGURE 8 ACUTE DIARRHEA IS THE LARGEST DISEASE SEGMENT IN THE MARKET Market Size ($Million) CAGR (%) Diabetes Obesity Autoimmune Disorders Cancer Acute Diarrhea Mental Disorders Others Source: World Health Organization World Cancer Research Fund International, United Nations Children's Fund, World Gastroenterology Organisation, International Diabetes Federation, Food and Drug Administration, National Cancer Institute, Centers for Disease Control and Prevention, Company Annual Reports, Company Press Releases, Investor Presentations, MarketsandMarkets Analysis TABLE 1 HUMAN MICROBIOME MARKET SIZE, BY DISEASE, ($MILLION) Diseases CAGR% ( ) Diabetes - Obesity - Autoimmune Disorders - Cancer - Acute Diarrhea - Mental Disorders - Other - Total - Source: World Health Organization World Cancer Research Fund International, United Nations Children's Fund, International Agency for Research on Cancer, World Gastroenterology Organisation, International Diabetes Federation, Food and Drug Administration, National Cancer Institute, Centers for Disease Control and Prevention, Company Annual Reports, Company Press Releases, Investor Presentations, MarketsandMarkets Analysis The acute diarrhea segment is expected to dominate the global human microbiome market in 2019 and is estimated to be the fastest-growing segment, growing at a CAGR of from 2019 to 2023, to reach $ million by Growing incidences and prevalence of diarrhea are fostering the growth of the acute diarrhea market. Several leading market players are focusing on increasing their market shares in the acute diarrhea market through various organic and inorganic growth strategies. 13

15 Obesity is the second leading human microbiome segment and is expected to witness many changes over the next five years owing to the growing public health problem in the developed and developing world. According to the WHO, obesity leads to 6.8 million deaths each year and the number is expected to reach million by Thus, the growing number of obesity cases is fueling the growth of the human microbiome disease market. Key players involved in human microbiome market include, Enterome Bioscience (France), Yakult Honsha Co. Ltd (Japan), Vithera Pharmaceuticals (U.S.), and Metabiomics Corporation (U.S.). 14

16 7 HUMAN MICROBIOME MARKET, BY APPLICATION 7.1 INTRODUCTION TABLE 2 GLOBAL HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, ($MILLION) Application CAGR% ( ) Therapeutics - Diagnostics - Total - Source: World Health Organization, United Nations Children's Fund, International Agency for Research on Cancer, World Gastroenterology Organisation, Food and Drug Administration, National Cancer Institute, Centers for Disease Control and Prevention, Company Annual Reports, Company Press Releases, Investor Presentations, MarketsandMarkets Analysis The therapeutic segment is expected to dominate the human microbiome applications market from 2019 onwards and is expected to grow at a CAGR of from 2019 to 2023, to reach $ million by This segment is estimated to be the fastest-growing segment and is expected to lead the human microbiome application market by This is mainly attributed to the identification of new and specific bacterial macromolecules as potential therapeutic targets and the need for reliable, precise, and quicker detection of chronic lifestyle diseases and various other disorders. Note: Diagnostic products are expected to be introduced in the market from 2021 onwards The, diagnostic segment is expected to enter the market in 2021 and estimated to grow at a CAGR of from 2021 to 2023, to reach $ million by However, limited awareness about microbiome-based applications and stringent regulatory policies are restricting the growth of this market. FIGURE 9 THERAPEUTICS IS THE FASTEST-GROWING SEGMENT IN THE GLOBAL HUMAN MICROBIOME APPLICATIONS MARKET APPLICATION DESCRIPTION CAGR% ( ) DRIVERS Therapeutics Microbiota plays an important role in the efficacy of therapeutic compounds Many therapeutic compounds are processed by catalytic functions encoded by mammalian symbiotic bacteria The unique nature of the human gut microbiome offers a new source of biomarkers The future of modulating the human microbiome may include the use of designed bacterial cells that deliver the chemicals, genes, or gene products necessary for disease management and treatment Need for reliable, precise, and quicker detection of chronic lifestyle disease and various disorders Enhancement in personalized medicines Diagnostics Possibility of mapping microbial fingerprints and defining microbial-derived biomarkers that identify individuals at risk of disease Better enable diagnosis of existing conditions and monitor efficacy of treatment Increasing number of biotechnology firms across the world focusing on the use of microbiome in diagnostic applications Advancement in research and technology innovation such as human genome mapping, omics technology, early detection and tailored treatment for individuals that helps improving cost-effectiveness of healthcare and improving patient outcomes Fastest-growing segment Projected to be leader in the global human microbiome applications market Expected to reach $ million by 2023 from $ million in 2019 Source: World Health Organization, United Nations Children's Fund, International Agency for Research on Cancer, World Gastroenterology Organisation, Food and Drug Administration, National Cancer Institute, Centers for Disease Control and Prevention, Company Annual Reports, Company Press Releases, Investor Presentations, MarketsandMarkets Analysis Prevention, Company Annual Reports, Company Press Releases, Investor Presentations, MarketsandMarkets Analysis 15

17 7.2 DIAGNOSTICS Human microbiome is expected to have a significant impact in diagnosing and treating human diseases. Due to development in personalized medicine the unique nature of the human gut microbiome offers a new source of biomarkers to distinguish between patients physiology and diseases. These also gave rise to an opportunity of mapping microbial fingerprints and define microbial-derived biomarkers that help in identifying individuals at risk of disease, better enable diagnosis of existing conditions and monitor efficacy of treatment. For instance, Paris-based Enterome raised $ million in venture capital for developing tests that use the composition of gut bacteria to diagnose inflammatory and liver diseases. Similarly, other companies are also focusing to turn the microbiome into a diagnostic tool. The market is expected to be active from 2021 onwards. It is estimated to be valued at $ million and it is poised to grow at a CAGR of during the forecast period to reach $ million in Fast growth in the development of molecular diagnostics such as cancer diagnostics and diagnostics linked to new medicine development is driving the growth of the market. Other factors contributing to the growth of this segment are automated and advanced instruments with high-throughput capacities, increase in number of biotechnology firms across the world that are focusing on the use of microbiome in diagnostic applications, advances in life science research and technology innovations with human genome mapping, emergence of omics technologies, and early detection and tailored treating diseases thereby improving the costeffectiveness of healthcare and improving patient outcomes. The human microbiome research would allow researchers to uncover the hereditary factors in virtually every disease with the help of human genome research, also help to predict future diseases, and adapt therapies to individual patients. This gives a better opportunity for the growth of market. The key barriers are regulatory approvals, and its adoption into mainstream clinical practice. Another important barrier for a microbiome-based diagnostics is that there will be the added potential complications of providing conclusive evidence of the link between potentially multiple biomarkers and disease states. FIGURE 10 EUROPE EXPECTED TO DOMINATE THE DIAGNOSTIC SEGMENTS 2021 ONWARDS North America Europe Asia-Pacific CAGR (%) RoW Source: World Health Organization World Cancer Research Fund International, United Nations Children's Fund, World Gastroenterology Organisation, International Diabetes Federation, Food and Drug Administration, National Cancer Institute, Centers for Disease Control and Prevention, Company Annual Reports, Company Press Releases, Investor Presentations, MarketsandMarkets Analysis 16

18 8 MARKET, BY PRODUCT 8.1 PROBIOTICS FIGURE 11 AWARENESS AMONG POPULATION & SAFETY OF PROBIOTICS IS EXPECTED TO FUEL THE GROWTH OF PROBIOTIC MARKET $Million CAGR (%) North America Europe Asia-Pacific ROW Source: World Health Organization World Cancer Research Fund International, United Nations Children's Fund, World Gastroenterology Organisation, International Diabetes Federation, Food and Drug Administration, National Cancer Institute, Centers for Disease Control and Prevention, Company Annual Reports, Company Press Releases, Investor Presentations, MarketsandMarkets Analysis TABLE 3 HUMAN MICROBIOME MARKET SIZE FOR PROBIOTICS, BY GEOGRAPHY, ($MILLION) Probiotic CAGR% ( ) North America - Europe - Asia-Pacific - ROW - Total - Source: World Health Organization World Cancer Research Fund International, United Nations Children's Fund, World Gastroenterology Organisation, International Diabetes Federation, Food and Drug Administration, National Cancer Institute, Centers for Disease Control and Prevention, Company Annual Reports, Company Press Releases, Investor Presentations, MarketsandMarkets Analysis Europe is expected to dominate the human microbiome probiotic market at an estimated $ million in 2019 and is expected to reach $ million by 2023, at a CAGR of. On the other hand, North America is expected to be the fastest-growing market with a CAGR of from 2019 to Leading players in the human microbiome product market include Enterome Bioscience (France), Yakult (Japan), DuPont (U.S.), Metabiomics Corporation (U.S.), ViThera Pharmaceuticals (U.S.), Second Genome, Inc. ( U.S.), MicroBiome Therapeutics LLC (U.S.), Vedanta BioSciences (U.S.), Osel, Inc. (U.S.), and Merck (U.S.). 17

19 9 GEOGRAPHIC ANALYSIS 9.1 INTRODUCTION The global microbiome market is predominantly segmented into four major geographies, namely, North America, Europe, Asia-Pacific, and the Rest of the World (ROW). Globally, biotechnology companies are identifying a large number of opportunities in the microbiome field. In Europe, in the recent years, several companies have emerged which are focusing on developing therapies that alter the microbiome for the benefit of human health. The global microbiome market is expected to be valued at $ million in 2019 and is projected to reach $ million by 2023, at a CAGR of. Europe is expected to account for the largest share of of the global microbiome market in The large share of this region can be attributed to its significant presence in the probiotics and prebiotics fields and the major acceptance of these products by the residing population. A number of factors such as the rising incidence of cardiovascular diseases, increasing awareness about the need for diagnostic and preventive care with less side-effects, and technological advancements are driving the growth of this market. In developed regions like North America, the microbiome market, in terms of value, is expected to be smaller as compared to Europe, owing to the slow acceptance of microbiome products in a number of countries in this region. However, North America is expected to grow at a high CAGR of during the forecast period.. FIGURE 12 GLOBAL HUMAN MICROBIOME MARKET: GEOGRAPHIC SNAPSHOT (2019) Market Share = CAGR = Market Share = CAGR = Market Share = CAGR = North America Europe Market Share = CAGR = Asia-Pacific Rest of the World Source: World Health Organization World Cancer Research Fund International, United Nations Children's Fund, World Gastroenterology Organisation, International Diabetes Federation, Food and Drug Administration, National Cancer Institute, Centers for Disease Control and Prevention, Company Annual Reports, Company Press Releases, Investor Presentations, MarketsandMarkets Analysis 18

20 10 COMPETITIVE LANDSCAPE 10.1 OVERVIEW This section of the report analyzes the strategies adopted by companies in the human microbiome market. The players implemented different strategies in order to uphold their position in the human microbiome market and ensure long-term growth. The key strategies implemented by most of the companies in the human microbiome market were agreements, collaborations and partnerships followed by clinical/research studies. FIGURE 13 COMPANIES ADOPTED AGREEMENTS, PARTNERSHIPS AND COLLABORATIONS AS THE KEY GROWTH STRATEGY OVER THE LAST THREE YEARS ORGANIC GROWTH STRATEGIES INORGANIC GROWTH STRATEGIES New Product Launches Expansions Clinical /Research Studies Partnerships/Agreements/Collaborations HOWARU Protect probiotics HOWARU Balance DuPont opened a new probiotic production facility in Beijing (China) Entered into a licensing agreement to manufacture and market AB-, a probiotic product Collaborated with Mayo Clinic to discover and validate a diagnostic test based on gut microbiome Filed clinical trial of Lactobcillus Casei Shirota to induce immune response in HIV patients Partnered with the Johnson & Johnson Corporate Office of Science and Technology (COSAT) to develop innovative microbiome treatment for inflammatory bowel disease Metabiomics launched the Metabiomics Neoplasia Clinical Research Study (MB-01) Partnered with Kindstar Global,a leading clinical testing laboratory to develop microbiome-based screening tests for colon polyps and colorectal cancer. Note - Indicates event that will have a significant impact on the market Source: Press Releases, Expert Interviews, and MarketsandMarkets Analysis 19

21 11 COMPANY PROFILES 11.1 ENTEROME BIOSCIENCE SWOT ANALYSIS STRENGTHS WEAKNESS Promising pipeline technologies Profound R&D capabilities Collaborations with leading health institutes S W Dependence on investors and grants or R&D expenses Limited geographic presence Emerging area of research Aging population and increasing prevalence of chronic diseases globally ENTEROME BIOSCIENCE O T Unpredictable future as research on microbiome is in the nascent stage Regulatory obstacles and difficulties in getting new health claims for functional ingredients New entrants in the market OPPORTUNITIES THREATS Source: Company Website, Press Releases, and MarketsandMarkets Analysis MNM VIEW Enterome is a pioneer in the development of personalized medical tests and companion diagnostics to rectify and manage microbiome-related diseases such as metabolic, gastrointestinal, and autoimmune diseases. The company is developing a new range of promising technologies for disease management and further designing new nutrition approaches for the treatments of inflammatory bowel and metabolic disorders. The company s robust pipeline is evident for its strong focus on R&D activities and it majorly focuses on the areas of inflammatory bowel diseases (IBD) and metabolic diseases. Since its establishment in 2012, the company has been developing innovative tests targeting IBD, obesity, and type - 2 diabetes. The company has adopted collaboration as its key strategy to achieve growth in the market. It recently collaborated with Mayo Clinic and Synthetic Biologics to discover and validate its pipeline tests, which would further facilitate commercialization and help it gain a prominent share in the human microbiome market. 20

22 Disclaimer: MarketsandMarkets strategic analysis services are limited publications containing valuable market information provided to a select group of customers in response to orders. Our customers acknowledge, when ordering, that MarketsandMarkets strategic analysis services are for our customers internal use and not for general publication or disclosure to third parties. Quantitative market information is based primarily on interviews and therefore, is subject to fluctuation. MarketsandMarkets does not endorse any vendor, product or service depicted in its research publications. MarketsandMarkets strategic analysis publications consist of the opinions of MarketsandMarkets' research and should not be construed as statements of fact. MarketsandMarkets disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. MarketsandMarkets takes no responsibility for any incorrect information supplied to us by manufac turers or users. All trademarks, copyrights and other forms of intellectual property belong to their respective owners and may be protected by copyright. Under no circumstance may any of these be reproduced in any form without the prior written agreement of their owner. No part of this strategic analysis service may be given, lent, resold or disclosed to non -customers without written permission. Reproduction and/or transmission in any form and by any means including photocopying, mechanical, electronic, recording or otherwise, without the permission of the publisher is prohibited. 21